Evaluation of serum thyroid hormones in female patients with melasma

Zhwan Amjad  Kamal; Ali Mozan Dhahir  Elethawi

doi:10.56056/amj.2022.151

Authors

Zhwan Amjad Kamal MBChB, KBMS/ Dermatology trainee, Sulaymaniyah dermatology teaching hospital, KRG, Iraq
Ali Mozan Dhahir Elethawi MBChB, CABD, FIBMS, Assistant Professor of Dermatology, University of Sulaymaniyah- College of medicine, Director of KBMS Sulaymaniyah center

DOI:

https://doi.org/10.56056/amj.2022.151

Keywords:

Melasma, Thyroid hormones, Dermal type

Abstract

Background & Objectives: Melasma is an acquired hyperpigmented patches dispersed symmetrically on body parts that are exposed to the sun, mostly on the faces of female patients. The precise etiology is obscure, but it has numerous hazards such as; ultraviolet exposure, genetic factors, and hormonal imbalances like thyroid hormone abnormalities. In this study, we aimed to evaluate serum thyroid hormone levels in melasma patients.

Methods: A complete of 51 female patients with melasma were enrolled during this study over a period of six months. The cases were clinically diagnosed and examined by Wood’s light, then sent for thyroid hormone levels assessment and the finding were reported.

Results: In the current study 51 females with melasma. Their ages ranged between (19-46) years, with (59.9%) between (28-38) years. The duration of melasma was from 6 months to 9 years. Thirty-eight of them were married and had pregnancy. Thyroid stimulating hormone levels were high in 22 of them (43.1%), 20 out of 22 cases that was had high levels of thyroid stimulating hormone had dermal type of melasma by Wood’s lamp examination and their p-value was significant (0.001).

Conclusion: We found significantly high levels of thyroid stimulating hormone in cases of melasma mainly among those of dermal type.

Downloads

Download data is not yet available.

References

Handel AC, Lima PB, Tonolli VM, Miot LD, Miot HA. Risk factors for facial melasma in women. Br J Dermatol. 2014; 171(3):588-94.

Li YH, Chen JZ, Wei HC et al. Efficacy and safety of intense pulsed light in treatment of melasma in Chinese patients. Dermatol Surg. 2008; 34(5):693-700. 3. Mogaddam MR, Alamdari MI, Maleki N, Ardabili NS, Abedkouhi S. Evaluation of autoimmune thyroid disease in melisma. J Cosmet Dermatol. 2015 Jun; 14(2):167-71. 4. Achar A, Rathi SK. Melasma: A clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011; 56(4):380-2.

Aboobacker S, Karthikeyan K. Melasma and hypothyroidism: conflicting coexistence? J Clin Exp Dermatol Res. 2017; 8(6):429-31.

Yenny SW, Lestari W. A study comparing the use of 10% L-ascorbic acid and 10% zinc sulfate solution in the treatment of melasma. Malaysian J Dermatol. 2012; 29:38-45.

Al-Shamma YM, Al-Wakeel HA, Al-Awadi IJ. The prevalence of thyroid disorders in patients with melasma. Al-Qadisiah medical journal. 2016; 12(21):107-11.

Qazi I, Dogra NK, Dogra D. Melasma: a clinical and epidemiological study. IJCMR. 2017; 4(10):2087-9.

Sarvjot V, Sharma S, Mishra S, Singh A. Melasma: A clinicopathological study of 43 cases. Indian J Pathol Microbiol. 2009; 52:357-9.

Martin M, Hameedullah A, Priya S. Unveiling the risk factors behind melasma: An observational study. IAIM. 2017; 4(11): 85-9.

Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014; 89(5):771-82. 12. Kiana A, Ahmari M, Rezvan FMR. Association of melasma with thyroid disorders: a case control study. Ir J Dermatol.2006;9:154-8.

Talaee R, Ghafarpasand I, Masror H. The relationship between melasma and disturbances in the serum level of thyroid hormones and indices. Med J. 2015; 2: 19-23.